AnaptysBio reports Phase IIa data for peanut allergy candidate

AnaptysBio Inc. (NASDAQ:ANAB) reported interim data from a Phase IIa trial showing that six of 13 (46%) patients exhibiting moderate to severe peanut allergy symptoms during a baseline oral food challenge improved their peanut tolerance to the maximum tested cumulative 500 mg dose of peanut protein at day 14 after a single 300 mg dose of IV ANB020 vs. zero of three patients who received placebo. The interim analysis excluded four patients with mild baseline peanut allergy symptoms. In all 20 patients, concomitant allergy symptoms, including urticaria, pruritus, rhinitis, asthma flares and other nut allergies, occurred in one of 15 (7%) patients in the ANB020 arm vs. four of five (80%) patients in the placebo arm.

ANB020 was generally well tolerated with no serious adverse events reported. The double-blind, U.S. trial's primary endpoint is safety. Secondary endpoints include change in clinical scores of oral food challenge symptoms, serum cytokine levels and pharmacokinetics...